A highlight on carbamazepine-induced adverse drug reactions in Saudi Arabia: a retrospective medical records-based study.

Autor: Sukkarieh HH; Department of Pharmacology, Alfaisal University, Riyadh, Kingdom of Saudi Arabia., Khokhar AA; College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia., Bustami RT; Department of Operations & Project Management, Alfaisal University, Riyadh, Kingdom of Saudi Arabia., Karbani GA; Department of Genetic Counseling, Alfaisal University, Riyadh, Kingdom of Saudi Arabia., Alturki FA; Department of Genetic Counseling, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia., Alvi SN; Department of Cell Biology, King Faisal Specialist Hospital & Research Centre, Riyadh, 11211, Kingdom of Saudi Arabia. salvi@kfshrc.edu.sa.
Jazyk: angličtina
Zdroj: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2023 Nov; Vol. 396 (11), pp. 3177-3182. Date of Electronic Publication: 2023 May 18.
DOI: 10.1007/s00210-023-02525-2
Abstrakt: The link between human leukocyte antigen (HLA) alleles and carbamazepine-induced cutaneous, respiratory, and gastrointestinal adverse drug reactions (ADR) has created a window of opportunity for preventing certain forms of cutaneous adverse drug reactions (cADRs); however, there is not enough data to make pharmacogenomic recommendations that can be implemented globally. The aim of this study is to assess and document carbamazepine-induced adverse reactions among prescribed Saudi/non-Saudi patients. A retrospective chart review was performed for patients who received carbamazepine (CBZ) in the period between 2016 and 2020, in the Kingdom of Saudi Arabia. Data were gathered and descriptive statistical analyses were performed on the data for the study sample. Comparisons were made using the chi-square test or independent samples' t-test. Statistical significance was considered at p < .05. All statistical analyses were performed using IBM SPSS 21.0 (Armonk, NY; IBM Corp). Results from multivariate logistic regression analyses showed that higher likelihood of carbamazepine-induced adverse reactions was significantly associated with younger age, OR = 0.82, 95% CI (0.74, 0.90); p < 0.001. Patients who were prescribed CBZ for reasons other than epilepsy or seizures were significantly more likely to develop carbamazepine-induced adverse reactions (epilepsy vs. other; OR = 0.63, p = 0.013; seizures vs. other; OR = 0.59, p = 0.018). Gender or medication duration were not related to carbamazepine-induced adverse reactions (p > 0.05). The findings of this study are comparable with those of other studies assessing carbamazepine-associated adverse reactions in children and adults. Recommendations include genetic prescreening, educating patients and parents on the possibility of adverse reactions, and routine laboratory monitoring.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: